Illumina (ILMN) was Downgraded by CL King to ” Neutral”. Earlier the firm had a rating of “Buy ” on the company shares. CL King advised their investors in a research report released on Aug 22, 2016.
Many Wall Street Analysts have commented on Illumina. Company shares were Reiterated by Mizuho on Jul 27, 2016 to “Neutral”, Firm has raised the Price Target to $ 148 from a previous price target of $138 .Shares were Downgraded by Morgan Stanley on Jul 5, 2016 to ” Underweight” and Lowered the Price Target to $ 110 from a previous price target of $130 .Illumina was Initiated by CL King to “Buy” on Jun 22, 2016.
On the company’s financial health, Illumina reported $0.71 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.74. The company had revenue of $571.80 million for the quarter, compared to analysts expectations of $580.44 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS.
Illumina closed down -0.7 points or -0.41% at $171.67 with 10,15,440 shares getting traded on Friday. Post opening the session at $171.83, the shares hit an intraday low of $169.81 and an intraday high of $174.07 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Aug 18, 2016, Daniel Bradbury (director) sold 600 shares at $168.42 per share price. According to the SEC, on Aug 16, 2016, Jay T Flatley (director) sold 10,000 shares at $170.00 per share price. On Aug 15, 2016, Roy A Whitfield (director) sold 4,000 shares at $167.22 per share price, according to the Form-4 filing with the securities and exchange commission.
Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.